Company intelligence / Profile preview

Advanced Aesthetic Technologies

Brookline, Massachusetts, USAalgeness.com ↗

Ownership: Private
Employees: ~5
Development stage: Commercial

Overview

Algeness® is clinically proven to be safe, fully biodegradable, biocompatible, and provides immediate volumizing effects with long-lasting results (>12 months). It has been shown to have a superior safety profile compared to traditional fillers and is currently used in over 30 countries. Ongoing pivotal trials are being conducted for regulatory approval in China.

Therapeutic areas: Dermatology
Modalities: DeviceHydrogel-based drug delivery therapy
Industry: Therapeutic Medical Devices

Drug pipeline

4 assets

Algeness DF

Commercial

Indications: Facial wrinkles, Volume loss

3 more assets in the full pipeline.

Request access →

Partnerships

Lanzhou Biotechnique Development Co., LTDChina National Biotec Group Co., LTD ("CNBG")

Beyond the preview

Go deeper on Advanced Aesthetic Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced Aesthetic Technologies.

Explore the full profile